Protocols

Buyout buzz centers on a Novartis NASH deal for Genfit; Synthon joins the CD47 club

→ Genfit $GNFT has become the target of the latest round of M&A rumors. StreetInsider says that Novartis is close to a deal to acquire France’s Genfit, which has been working on a new drug for NASH, now in Phase III.

→ You can welcome the Dutch biotech Synthon to the ranks of CD47 drug developers. Synthon has licensed worldwide rights to Sanquin’s lead antibodies and IP regarding the CD47-SIRPα pathway to develop new immuno-oncology treatments.

→ Dublin-based Prothena {PRTA} has sold 2,700,000 of its ordinary shares at a price to the public of $57.50 per ordinary share.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Clinical Scientist
Molecular Templates Jersey City, NJ
Manufacturing Associate - GMP Upstream
Molecular Templates Austin, TX
Director, Regulatory Affairs
Molecular Templates Jersey City, NJ
GMP Supervisor - Downstream
Molecular Templates Austin, TX
Manufacturing Associate - GMP Downstream
Molecular Templates Austin, TX

Visit Endpoints Careers ->